Company profile
APTEVO THERAPEUTICS INC.
NASDAQ:APVOBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OTLERTUZUMAB | phase1_2 | — | 4 | completed, terminated |
| APVO-414 | phase1 | — | 1 | no active trials |
| MIPLETAMIG | phase1 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01317901 | phase1 | completed | 2011-05-01 | 2013-04-01 | Aptevo Therapeutics | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma |
| NCT05934539 | phase1_2 | unknown | 2022-12-23 | 2024-01-01 | Aptevo Therapeutics | ALG.APV-527 First-in-human Study |
| NCT06634394 | phase1 | recruiting | 2024-10-01 | 2027-10-01 | Aptevo Therapeutics | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML |
| NCT00614042 | phase1 | completed | 2008-01-01 | 2011-12-01 | Aptevo Therapeutics | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma |
| NCT01644253 | phase1 | terminated | 2012-09-01 | 2020-02-24 | Aptevo Therapeutics | Phase 1b Safety and Efficacy Study of TRU-016 |
FDA applications (0)
No records yet.